Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report.
The case of a female patient with acute lymphoblastic leukaemia and chronic disseminated candidiasis, who was refractory to 1.8 g conventional amphotericin B therapy, is reported. She experienced severe amphotericin-B-related side-effects in spite of pretreatment, but was subsequently successfully treated with 3 g of a small unilamellar liposome formulation of amphotericin B prepared from soya phosphatidylcholine and cholesterol in a 7:3 molar ratio at our institute. The patient experienced minimal side-effects with this preparation, although no pretreatment was given. Liposomal amphotericin B prepared in our institute appears to be a safe and effective therapy for systemic fungal infections. However, large controlled studies are required to determine more precisely the potential of liposomal amphotericin B in the treatment of severe systemic fungal infection.
Gokhale
P C
PC
Department of Pharmacology, Seth G.S. Medical College, Parel, Bombay, India.
Barapatre
R J
RJ
Advani
S H
SH
Kshirsagar
N A
NA
Pandya
S K
SK
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy* / Q000209:etiology; D004337:Drug Carriers; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000150:complications; D008081:Liposomes
D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B